childhood acute lymphoblastic leukemia
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia
... transversion at codon 270 (phenylalanine to cysteine) and a G to C transversion at codon 248 (arginine to proline). These data support the role of both hereditary and acquired p53 mutations in the pathogenesis and/or ...
9
A Multicenter Retrospective Analysis on the Treatment Pattern and Outcome in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia
... Fig. 1. The Kaplan-Meier estimates of overall survival rate (OS). (A) The 5-y OS of all 63 patients with relapsed/refractory (R/R) childhood acute lymphoblastic leukemia (ALL) was 6.7%. (B) ...
6
Evaluation of bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia
... Patients and Methods: This was a 5 year prospective study comprised of thirty-one survivors of childhood acute lymphoblastic leukemia with a mean age of 11.8 (4.6) years, who completed therapy ...
7
Lymphomatoid Granulomatosis After Childhood Acute Lymphoblastic Leukemia: Report of Effective Therapy
... condition in children. Although it affects the lungs primarily, it may have significant extrapulmo- nary manifestations, especially in the central nervous system. We report a case of lymphomatoid granulo- matosis with ...
7
Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia
... in childhood ALL patients in developed countries, but few have been conducted in developing countries, where sup- portive care for ALL patients is limited ...in childhood acute lymphoblastic ...
8
MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
... Abstract: Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme ...
10
Dexamethasone versus Prednisone in Childhood Acute Lymphoblastic Leukemia Treatment: Results of the Indonesian Randomized Trial
... Steroids, either prednisone or dexamethasone, are essential drugs in the remission induction phase of childhood acute lymphoblastic leukemia (ALL) treatment based on their activity against ...
16
The EPHX1 rs1051740 Polymorphism Is Associated with Childhood Acute Lymphoblastic Leukemia in a Korean Population
... for childhood acute lymphoblastic leukemia (ALL) in Korean children, we genotyped two SNPs, Tyr113His (rs1051740) and His139Arg (rs2234922) in 185 childhood ALL cases and 536 healthy ...
8
Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia
... involving childhood acute lymphoblastic leukemia (ALL), where each patient may receive up to 13 different anticancer agents over a period of 2-3 ...use childhood ALL therapy as a model ...
12
Genetic markers in a multi-ethnic sample for childhood acute lymphoblastic leukemia risk.
... Our study did have a well-defined phenotype, with molecular ALL types determined. The use of a multi-ethnic sample population was a strength, especially for the ethnic disparity that exists in childhood ALL ...
26
WILMS' TUMOR GENE 1 (WT1) EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
... Subjects &Methods:An case-control study was conducted in pediatric Hematology & oncology unit ,zagazig university children's ٰ hospital ,zagazig university during the period of January 2011 to June 2013.we ...
5
Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemia.
... Swiss Childhood Cancer Registry: current age; gender; age at diagnosis; time since diagnosis; chemo- and radiotherapy (chemotherapy: without radiotherapy, may have surgery/radiotherapy: with or without ...
8
Clonal analysis of childhood acute lymphoblastic leukemia with "cytogenetically independent" cell populations
... Immunoglobulin and T cell receptor gene rearrangement and RFLP analyses in these cases provided evidence for multistep leukemogenesis and suggested that both stem lines were derived from[r] ...
8
Survivorship care plan experiences among childhood acute lymphoblastic leukemia patients and their families
... of childhood cancer found that distribution of SCPs along with a directed PCP visit was not sufficient to improve adherence to guideline-recommended surveillance compared to sur- vivors seen in a survivorship ...
9
Late effects in survivors of childhood acute lymphoblastic leukemia in the context of selected gene polymorphisms
... the childhood cancer survivors, particularly those who have completed their therapy long time ago, to participate in conferences and use internet resources to provide them with access to comprehensive information ...
8
Identification and evaluation of novel prognostic genetic markers for childhood acute lymphoblastic leukemia
... the leukemia- associated translocations, including the t(12;21) ETV6/RUNX1 fusion, can be present already before birth in children who later develop leukemia, but also in children who do not develop this ...
56
Original Article CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia
... Acute lymphoblastic leukemia (ALL) is the most common malignant disorder in childhood and the incidence is increasing ...extramedullary leukemia has been an important mean in the ...
7
COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia
... in leukemia was published ...40 leukemia patients [6], which identified again recurrent submicroscopic deletions in several genes linked to B-lineage development (PAX5, EBF1, TCF3, IKZF1 and ...that ...
10
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia
... Swedish Childhood Cancer Foundation. M.E. Figueroa is supported by a Leukemia and Lymphoma Society Spe- cial Fellow award and a Clinical Scientist Development Award from the Doris Duke Charitable ...a ...
14
Treatment related deaths in childhood acute lymphoblastic leukemia
... Regarding participation to different protocols, it was identified that having been treated in the 58831/2 trial was significantly associated with an increased risk of death before remission when compared with the 58881. ...
154